Indiplon: Indiplon modified-release, Indiplon MR, NBI 34060, NBI 34060 modified-release, NBI 34060 MR

Drugs in R and D

Volumn 3, Issue 3, 2002, Pages 197-199

  Tanghetti, Elena ^a   Ria, Roberto ^b   Dell‘Era1, Patrizia ^a   Urbinati, Chiara ^a   Rusnati, Marco ^a   Ennas, Maria Grazia ^c   Presta, Marco ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^c UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; HYPNOTIC SEDATIVE AGENT; INDIPLON; INDIPLON MR; NBI 34060 MR; PLACEBO; UNCLASSIFIED DRUG; ZOLPIDEM; ZOLPIDEM TARTRATE; ZOPICLONE; BENZODIAZEPINE DERIVATIVE; THIOPHENE DERIVATIVE;

ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG RELEASE; DRUG SAFETY; DRUG STRUCTURE; HANGOVER; HUMAN; INSOMNIA; PRIORITY JOURNAL; SEDATION; SLEEP INDUCTION; STRUCTURE ANALYSIS; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG INDUSTRY; METHODOLOGY; STATISTICS;

BENZODIAZEPINES; CLINICAL TRIALS; DELAYED-ACTION PREPARATIONS; DRUG INDUSTRY; HYPNOTICS AND SEDATIVES; SLEEP INITIATION AND MAINTENANCE DISORDERS; THIOPHENES;

EID: 0036050925     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200203030-00012     Document Type: Article

References (5)

1. Neurocrine Biosciences, Inc. Neurocrine Biosciences, Inc. reports positive phase II results with new insomnia drug. Media Release: [3 pages], 30 Nov 1999. Available from URL: http://www.neurocrine.com
2. Neurocrine Biosciences Inc. Neurocrine Biosciences announces positive results from phase I and II clinical trials with NBI-34060. Media Release: [3 pages], 8 Jan 2001. Available from URL: http://www.neurocrine.com
3. Neurocrine Biosciences Inc. Neurocrine Biosciences announces positive phase II results with NBI-34060 in patients with chronic insomnia. Media Release: [2 pages], 17 Jul 2001. Available from URL: http://www.neurocrine.com
4. Neurocrine Biosciences Inc. Neurocrine Biosciences announces positive phase II efficacy results with NBI-34060 immediate release in elderly patients with primary (chronic) insomnia. Media Release: [4 pages], 14 Dec 2001. Available from URL: http://www.neurocrine.com
5. Neurocrine Biosciences Inc. Neurocrine Biosciences announces positive phase II efficacy and safety results with NBI-34060 modified release (MR). Media Release: [2 pages], 18 Jan 2002. Available from URL: http://www.neurocrine.co